… the rationale for checkpoint inhibitors in lung cancer, recent … death protein‐1 (PD‐1)
pathway inhibitors have entered routine … of immune checkpoint inhibitors in lung cancer for the …

… checkpoint inhibitors for the treatment of cancer has led to major changes to the therapeutic
landscape of lung cancer… non–small cell lung cancer (NSCLC) who are treated with immune …

… support, the treatment of lung cancer has entered a new era. … immune checkpoint inhibitors
used for treating lung cancer. … side effects of immune checkpoint inhibitors are very different …

… (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib. Immune checkpoint inhibitors are
a new … the efficacy of immune checkpoint inhibitors compared with other chemotherapies in …

… a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting
PD-1 and PD-L1 are approved for the treatment of patients with non-small-cell lung cancer, with …

… lung cancer can be divided into two main subtypes: small cell lung cancer (SCLC) and non-small
cell lung cancer (… squamous cell carcinoma, adenocarcinoma large cell carcinoma, and …

… Cell Non–Small Cell Lung Cancer [NSCLC]), the parallel trial in patients with squamous cell
lung cancer, … PD-L1 tumor expression was neither prognostic nor predictive of response.50 …

… checkpoint inhibitors has already become a new and important treatment modality for lung
cancer in … experience with these antibodies in nonsmall cell lung cancer (NSCLC) treatment. …

… These immune checkpoint inhibitors have established … cancer types including non-small
cell lung cancer (NSCLC). Evaluation of the CTLA-4 inhibitor, ipilimumab and PD-1 inhibitors, …

… Immune checkpoint blockade has been a pivotal development in the management of advanced
non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved …